Another bispecific anti-DLL4/VEGF antibody, ABT-165, outperformed tumor response with single anti-VEGF treatment in preclinical models of glioma, breast cancer, and colon cancer alone and in combination with standard-of-care chemotherapy drugs [236]. This evidence concerns the gene VEGFA and central nervous system cancer.